parsatuzumab (RG7414) / Roche - LARVOL DELTA

Genetic Basis of Early Onset Atrial Fibrillation in Patients without Risk Factors. (PubMed, J Cardiovasc Dev Dis) - "We observed a high prevalence of pathogenic/likely pathogenic variants in cardiomyopathy-associated genes in patients with risk factor-free early-onset AF. Moreover, our follow-up imaging data indicate that these types of patients are at risk of developing ventricular dilation. Furthermore, we identified two TTNtvs founder variants in our Latvian study population."

Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Heart Failure • TTN

Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma (ASH 2021) - "Currently, MCL patients are treated with aggressive chemo-immunotherapy regimens followed mostly by consolidation with autologous stem cell transplantation and maintenance rituximab...To examine the therapeutic potential of targeting EGFL7 in MCL cells, we treated patient-derived xenograft (PDX) cells (n=3) with an anti-EGFL7 blocking antibody (Parsatuzumab) in vitro...Further, Anti-EGFL7 treatment decreased phospho-AKT protein levels in PDX cells and MCL cell lines compared to IgG control, suggesting blocking EGFL7 abrogates EGFR mediated downstream signals. In conclusion, this is the first report describing a role for EGFL7 in MCL growth and/or survival by modulating the EGFR-AKT signaling pathway and targeting EGFL7 using an anti-EGFL7 blocking antibody as a novel treatment to improve the outcome for MCL patients."

IO biomarker • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Study evaluating the safety and efficacy of MEGF0444A in combination with carboplatin, paclitaxel and bevacizumab in patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy for advanced disease (clinicaltrials.gov) - P2, N=100; NILE; Recruiting; Completion date: NA -> Jun ‘14

Completion date • Non Small Cell Lung Cancer • Oncology

Study evaluating the safety and efficacy of MEGF0444A in combination with carboplatin, paclitaxel and bevacizumab in patients with advanced or recurrent non-squamous non small cell lung cancer who have not received prior chemotherapy for advanced disease (clinicaltrials.gov) - P2, N=100; Not yet recruiting → Recruiting

Enrollment open • None • Oncology

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (clinicaltrials.gov) - P2; N=104; Completed; Sponsor: Genentech; Trial primary completion date: Apr 2014 ->Feb 2013

Trial primary completion date • Biosimilar • Non Small Cell Lung Cancer • Oncology

Chugai Pharma: Q1 2014 Results (Chugai) - Development discontinued for solid tumors

Discontinued • Oncology

Roche: Late-Stage Pipeline Event (Roche) - Anticipated regulatory submission in EU for solid tumors in 2016 or after; Anticipated regulatory submission in US for solid tumors in 2016 or after

Anticipated EU regulatory • Anticipated FDA event • Oncology

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. (PubMed, Oncologist) - "There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC."

Biomarker • Clinical • Combination therapy • Journal • P2 data